Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0476089 (endometrial cancer)
 11,379 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Gestrinone (R 2323) is a synthetic progestogen, and noteworthy agent for endometriosis treatment. The effect of this reagent on cultured cells from porcine granulosa, human endometrial and endometrial carcinoma origin was investigated concerning their hormonal activities and cell proliferations. Also, the effect of gestrinone on the serum levels of gonadotropins and gonadal steroids in patients with XY gonadal dysgenesis (Swyer's syndrome) and uterine myoma was studied. The monolayer cell colony established from the endometrial tissue fragments was positively stained by PAS similar to the secretory phase endometrium by 10 ng/ml gestrinone in the culture media. Endometrial carcinoma cells from a 65-year-old patient were proliferated by gestrinone at the concentration of 50 ng/ml in the culture media. The effect of gestrinone on the secretions of progesterone and estradiol-17 beta with or without hCG/testosterone from the cultured porcine granulosa cells was also investigated. Progesterone secretions were stimulated at the 50 ng/ml concentration of gestrinone, especially in association with hCG. Nonetheless, at the concentration of 500 ng/ml, those were inhibited. The secretions of estradiol-17 beta were stimulated by this reagent both with and without testosterone in dose-dependent manners. The effect of 25 mg gestrinone administration for 3 days on the levels of LH, FSH, progesterone and estradiol-17 beta in a patient with XY gonadal dysgenesis was as follows. Both LH and FSH levels gradually decreased, whereas estradiol-17 beta level was increased. The same dosage of this reagent was administered to a patient with uterine myoma on her menstrual days 7, 8, and 9.(ABSTRACT TRUNCATED AT 250 WORDS)
 ...
PMID:[The effect of a synthetic progestin (R 2323) on gonadal and endometrial cells in vitro and in vivo]. 385 23

Tissue polypeptide antigen (TPA) was measured by radioimmunoassay in sera from patients with various gynecologic tumors: 64 uterine myomas, 129 cervical cancers, 31 endometrial cancers, and 173 ovarian tumors (89 benign, 18 low-grade malignant (LGM) and 66 malignant tumors). Among the cervical cancer patients, the incidence of elevated TPA levels increased with stage of disease from 12% in the preinvasive stage to 67% in the advanced stage. Similarly, the TPA values were elevated in 35% of the endometrial cancer patients. Among the patients with ovarian malignancies, serum TPA was elevated in the following order: LGM cases (33%), Stage I (44%), and advanced (88%). Serum TPA values varied directly with the stage and malignancy of disease, and also correlated with the effect of treatment. However, serum TPA was elevated in 22% of the patients with uterine myoma and in 12% of those with ovarian benign tumors. The current observations demonstrate that the lack of tumor specificity of TPA limits its diagnostic value in gynecologic malignancies, but that serial measurements of this antigen appear to be useful for the evaluation of therapy and monitoring of patients.
 ...
PMID:The clinical value of tissue polypeptide antigen in patients with gynecologic tumors. 399 74

It was shown that the risk for endometrial cancer development in uterine myoma increases 43-fold in cases of diabetes mellitus, hypertension and obesity, 20-fold in adnexitis, 15-fold in hyperplastic endometrial lesions and 9.8-fold in the multipara.
 ...
PMID:[Risk factors for the development of endometrial cancer in uterine myoma]. 402 48

Patients with endometrial carcinoma (N = 1113) were treated by conventional therapy, using surgery and radiotherapy, complemented by daily administration of 100 mg oral medroxyprogesterone acetate (MPA) for a 2-year period. Only 7.3% of the malignancies were at an advanced clinical stage (III or IV), whereas 75.9 and 16.8% of the carcinomas were detected at clinical stages I and II, respectively. The 5-year survival rate was 71.0% overall, and 77.8%, 61.0, 29.0, and 5.3 for clinical stages I, II, III, and IV, respectively. Patients with anaplastic carcinoma (grade 3) at all clinical stages had significantly lower survival rates than had patients with well-differentiated (grade 1) and moderately differentiated (grade 2) adenocarcinomas. Death of grade 1, grade 2 and grade 3 endometrial carcinoma during the first 2 years occurred in 4.7, 6.8, and 18.2% of cases, respectively, in stage II, indicating that adjuvant MPA cannot totally prevent the progression of endometrial malignancy. The incidence of anaplastic endometrial carcinoma increased with the spread of the disease. It often appeared in patients with low body weight or a second invasive malignancy, but seldom occurred in young patients or patients with diabetes, uterine myoma, or a history of previous estrogen use. The worsened prognosis associated with old age, low body weight, and presence of a second invasive malignancy thus seems at lest partly due to the increased incidence of anaplastic carcinoma, which, on the other hand, did not contribute to the decreased 5-year survival rate of patients with diabetes or severe hypertension.
 ...
PMID:Clinical outcome in endometrial cancer. 621 34

Immunosuppressive acidic protein (IAP) was determined in sera of patients with gynecologic tumors using the single radial immunodiffusion method. The normal limit of IAP of 490 micrograms/ml was derived from the mean value + 2 SD of IAP in 150 healthy females. Among 141 patients with gynecologic cancers, serum IAP was elevated in 87 patients (62%). Among 190 patients with benign tumors (98 uterine myoma, 92 benign ovarian tumors) serum IAP was elevated in 14 patients (7%). Elevated levels of IAP were recognized in 43% of 77 patients with cervical cancer, in 55% of 11 endometrial cancer patients, and in 91% of 53 ovarian cancer patients. The frequency of elevated levels showed a tendency to increase with advancing stage of disease. In ovarian cancer elevation of IAP was observed even in early stages. All of 13 patients with recurrent cervical cancer had elevated IAP while only 6 of 35 (17%) previously treated patients without evidence of recurrence had elevated IAP. Immunosuppressive acidic protein determinations may be useful in monitoring the recurrence of cervical cancer. The measurement of serum IAP as a marker for gynecologic cancer is recommended as an addition to diagnostic procedures.
 ...
PMID:Immunosuppressive acidic protein in patients with gynecologic cancer. 674 2

The values of pO2 and pCO2 were determined in the uterine cavity by a medical mass spectrometer (MEDSPECT-MS80) in 45 cases of uterine myoma, 26 cervical carcinoma, 6 endometrial carcinoma and 20 normal uterus cases. The uterine tissue pO2 and pCO2 correlated with the pO2 and pCO2 determined in the uterine cavity or cervical canal. No statistically significant change of pO2 nor pCO2 was noted between the values of uterine cavity and cervical canal. The pO2 was higher and pCO2 was lower in the luteal phase than proliferative in 7 menstrual cycles. The mean values of intracavitary pO2 and pCO2 were 22.5 +/- 5.3 mmHg, 53.5 +/- 5.1 mmHg respectively in the cases of uterine myoma, 23.6 +/- 5.6 mmHg, 60.7 +/- 7.6 mmHg in cervical carcinoma, 20.8 +/- 1.0 mmHg, 54.5 +/- 3.7 mmHg in endometrial carcinoma and 28.5 +/- 4.3 mmHg, 53.5 +/- 5.1 mmHg in normal control uterus respectively. The intracavitary pO2 was lower and pCO2 was higher in the cases of uterine neoplasm than the control, and particularly the pCO2 was significantly higher in cervical carcinoma than the control.
 ...
PMID:[Studies on the levels of pO2 and pCO2 in the uterine cavity and uterine tissue (author's transl)]. 679 30

Immunosuppressive acidic protein (IAP) was determined in sera of patients with gynecologic tumors and pregnant women using the single radial immunodiffusion method. The normal limit of IAP of 490 micrograms/ml was derived from the mean value +2S.D. of IAP in 150 healthy females. Among 141 patients with gynecologic cancers, serum IAP was elevated in 87 patients (62%). Among 190 patients with benign tumors (98 uterine myoma, 92 benign ovarian tumors) serum IAP was elevated in 14 patients (7%). The level of IAP in sera of 201 pregnant women was almost identical with that of the healthy females. Elevated levels of IAP were recognized in 43% of 77 patients with cervical cancer, in 55% of 11 endometrial cancer patients and in 91% of 53 ovarian cancer patients. IAP determination was most effective in ovarian cancer for the early detection of cancer. IAP determinations may provide a useful method for the detection of recurrence of cervical cancer.
 ...
PMID:[Variations in the level of immunosuppressive acidic protein in patients with gynecologic tumors and pregnant women]. 688 5

Such features as single-phase cycling, endocrine infertility, endometriosis concomitant endometrial hyperplasia, endometrial carcinoma and endometriosis with concomitant uterine myoma and proliferative processes in the mammary glands as well as hormono-metabolic disorders frequently occur both in endometriosis and endometrial carcinoma and, therefore, suggest that pathogenesis of these hormone-dependent diseases has something in common. It was established experimentally that the likelihood of proliferation development and malignancy in the endometrium is great, when it is dislocated and, particularly, when hormonal disorders occur. An autoimmune nature of endometriosis is suggested. The similarity and differences in diagnosis of endometriosis and some types of cancer as well as common principles of treatment of the diseases are discussed. It is recommended in conclusion that patients with endometriosis of the uterus, ovary and other sites should be referred to a group at high risk for cancer.
 ...
PMID:[Endometriosis and cancer]. 706 18

The aim of study was to estimate the utility of Vabra aspirator in the screening of endometrial carcinoma. For this and 656 patients aged over 40 were subjected to cytologic examination and we compared the date obtained with the histologic examination, when the woman was subjected to surgical operation. The research which we carried out was of the retrospective type and it lasted two years. The patients were recruited at the division out-clinic and locally. All the examinations were carried out at the division, using the method of Vabra aspirator with the Kit of Sterilab. The patients admitted to examination showed some menstrual anomalies, (spotting, abnormal uterine bleeding, metrorrhagias and after postmenopausal uterine bleeding), and stayed at our USSL or at neighbouring ones. The cytologic examination have been read beside a single centre and the cytologic diagnosis has been compared with the histology one on the operating organ. The result obtained agrees with the literature. In fact, out of 888 screened women, 656 were aged over 40 and 232 aged less than 40. In the group of 656 patients 3 adenocarcinoma have been diagnosed and 4 atypical hyperplasia, equivalent to 0.33% and to 0.45% respectively. In conclusion, we can say that the method has shown a good diagnostic reliability into the diagnosis of malignant neoplasia. According to other authors, its limit is, instead, the high number of inadequate, besides the impossibility to diagnose other uterine pathologies, such as the endometrial polyps and the uterine myoma.(ABSTRACT TRUNCATED AT 250 WORDS)
 ...
PMID:[The role of the Vabra aspirator in the screening of endometrial carcinoma. Our experience]. 825 98

We performed Doppler studies of the uterine artery in 85 women with postmenopausal and perimenopausal bleeding. Sixty-six women had non-malignant changes and 19 women had malignant changes on histologic examination of the endometrium. Uterine fibroids were detected in 30 women. When malignant changes were detected in the endometrium, uterine artery resistance index was always below 0.83. The mean uterine artery resistance index was significantly lower in the group of women with pathologic changes of the endometrium (RI = 0.77 +/- 0.03) compared to the group with non pathologic changes (RI = 0.85 +/- 0.08 p < 0.01), excluding the women with uterine fibroids. The lowest mean resistance index in the uterine artery was observed in the group of women with uterine fibroids (RI = 0.60 +/- 0.09 p < 0.001). In five of six patients with endometrial carcinoma blood vessels were detected around the myometrium by using color flow imaging. Their RI was always less than 0.5. In five patients, blood vessels were detected in uterine fibroids but their RI was always more than 0.5. All six women with endometrial carcinoma but only seven of 13 women with endometrial hyperplasia, had endometrial thickness greater than 5 mm. Doppler velocimetry of the uterine artery carries a high sensitivity (100%) in detecting pathological changes of the endometrium in patients presenting with postmenopausal or perimenopausal bleeding. The presence of high resistance in this vessel, may allow a more conservative approach in this group of patients.
 ...
PMID:Uterine artery flow velocity waveforms and color flow imaging in women with perimenopausal and postmenopausal bleeding. Correlation to endometrial histopathology. 838 49


<< Previous 1 2 3 4 5 Next >>